MedTrace Logo

Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis

NCT02275741 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2018-11-27

No results posted yet for this study

Summary

The aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(MS) under MS-specific therapy.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL

prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)

Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description

Sponsors & Collaborators

  • Dr. med. Micha Loebermann

    lead OTHER

Principal Investigators

  • Uwe K Zettl, Prof. Dr. · University of Rostock

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2015-09-30
Completion
2016-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275741 on ClinicalTrials.gov